Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-ascending Dose, Multiple-ascending Dose, and Multi-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN AS1 in Patients With Acute Intermittent Porphyria (AIP)

Trial Profile

A Phase 1, Single-ascending Dose, Multiple-ascending Dose, and Multi-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN AS1 in Patients With Acute Intermittent Porphyria (AIP)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Givosiran (Primary)
  • Indications Acute intermittent porphyria
  • Focus Adverse reactions
  • Acronyms EXPLORE
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 14 Aug 2019 According to an Alnylam Pharmaceuticals media release, results from this study will be presented at the 2019 International Congress on Porphyrins and Porphyria (ICPP).
    • 16 Mar 2019 Results presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 06 Feb 2019 According to an Alnylam Pharmaceuticals media release, the results were published online today in The New England Journal of Medicine (NEJM). The manuscript will appear in the February 7, 2019 issue of NEJM.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top